The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Can Systemic Inflammation Influence Mood?

Can Systemic Inflammation Influence Mood?

August 17, 2015 • By Simon M. Helfgott, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Rheumatologists routinely deal with mood issues that may shroud the benefits of the drugs we prescribe.

Rheumatologists routinely deal with mood issues that may shroud the benefits of the drugs we prescribe.
Image Credit: Bruce Rolff/shutterstock.com

The Friday night press release: When a politician or any public figure needs to disclose unfavorable news, chances are they will release it sometime on a late Friday afternoon or evening, hoping that nobody is paying attention. In fact, this behavior was coined “the take out the trash day” on the television political drama, The West Wing. The likelihood of a press release fading into oblivion gets even better whenever it is disclosed on the Friday before a long weekend break. Guaranteed to achieve complete obscurity, or so claim the consultants who specialize in these sorts of things.

You Might Also Like
  • The Type I Interferon Pathway’s Influence in Connective Tissue Disease
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis
  • Inflammation & Psych Issues: A Look at Potential Co-Morbidity
Explore This Issue
August 2015
Also By This Author
  • Inflammatory Origin of Fever Is Key to Diagnosis

The press release dated Friday, May 22, 2015, at the start of the Memorial Day long weekend was decidedly low key.1 Most of its 1,200-plus words consisted of boilerplate jargon, but the first sentence said it all: “Amgen today announced (it) has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca. Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. The decision was based on events of suicidal ideation and behavior in the brodalumab program, which Amgen believes likely would necessitate restrictive labeling.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Have I read this correctly? Do we have our drug classes confused? As rheumatologists, we are accustomed to dealing with mood issues that may shroud the benefits of some of the drugs that we prescribe: Pain-modifying medicines, such as pregabalin and tramadol, are frequent offenders, and rarely, antimalarial agents, such as hydroxychloroquine, precipitate nightmares. Of course, corticosteroids are the greatest mood-offending drugs we prescribe. How often have we witnessed a troubling steroid-induced mood swing or, even worse, the unmasking of an underlying psychosis? Even lower doses of steroids are not immune, because they too can create feelings of anxiety or depression in some individuals.

In contrast, scant evidence implicates biological therapies as drivers of mood disorders. One exception may be belimumab. The data submitted to the Food and Drug Administration (FDA) by its manufacturer included information on a total of seven suicide attempts that were recorded in the various study protocols of this anti-B cell therapy.2 To use drug-study parlance, three were completed suicides. In contrast, data derived from the FDA’s spontaneous report system concluded that the rate of suicide and depression among users of TNF-inhibiting drugs was not disproportionate to the frequency of their use.3 This latter observation is in keeping with what we see in clinical practice. If anything, because biological therapies frequently enhance the quality our patients’ lives, they may indirectly improve their mood.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Opinion, Practice Management, Rheuminations, Systemic Inflammatory Syndromes Tagged With: disorder, drug therapy, Mental Health, mood, patient care, Psychosis, rheumatologist, Steroid, systemic inflammationIssue: August 2015

You Might Also Like:
  • The Type I Interferon Pathway’s Influence in Connective Tissue Disease
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis
  • Inflammation & Psych Issues: A Look at Potential Co-Morbidity
  • POP1-Based Treatments May Reduce Inflammation

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)